ABSTRACT
Professional antigen-presenting cells (APC; myeloid dendritic cells [DC] and macrophages [MΦ]; B lymphocytes) mediate highly efficient HIV-1 infection of CD4
+
T cells, termed
trans
infection, that could contribute to HIV-1 pathogenesis. We have previously shown that lower cholesterol content in DC and B lymphocytes is associated with a lack of HIV-1
trans
infection in HIV-1-infected nonprogressors (NP). Here, we assessed whether HIV-1
trans
infection mediated by another major APC, MΦ, is deficient in NP due to altered cholesterol metabolism. When comparing healthy HIV-1 seronegatives (SN), rapid progressors (PR), and NP, we found that monocyte-derived MΦ from NP did not mediate HIV-1
trans
infection of autologous CD4
+
T cells, in contrast to efficient
trans
infection mediated by SN and PR MΦ. MΦ
trans
infection efficiency was directly associated with the number of DC-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN)-expressing MΦ. Significantly fewer NP MΦ expressed DC-SIGN. Unesterified (free) cholesterol in MΦ cell membranes and lipid rafting was significantly lower in NP than PR, as was virus internalization in early endosomes. Furthermore, simvastatin (SIMV) decreased the subpopulation of DC-SIGN
+
MΦ as well as
cis
and
trans
infection. Notably, SIMV decreased cell membrane cholesterol and led to lipid raft dissociation, effectively mimicking the incompetent APC
trans
infection environment characteristic of NP. Our data support that DC-SIGN and membrane cholesterol are central to MΦ
trans
infection, and a lack of these limits HIV-1 disease progression. Targeting the ability of MΦ to drive HIV-1 dissemination in
trans
could enhance HIV-1 therapeutic strategies.
IMPORTANCE
Despite the success of combination antiretroviral therapy, neither a vaccine nor a cure for HIV infection has been developed, demonstrating a need for novel prophylactic and therapeutic strategies. Here, we show that efficiency of MΦ-mediated HIV
trans
infection of CD4
+
T cells is a unique characteristic associated with control of disease progression, and it is impaired in HIV-infected NP.
In vitro
treatment of MΦ from healthy donors with SIMV lowers their cholesterol content, which results in a strongly reduced
trans
infection ability, similar to the levels of MΦ from NP. Taken together, our data support the hypothesis that MΦ-mediated HIV-1
trans
infection plays a role in HIV infection and disease progression and demonstrate that the use of SIMV to decrease this mechanism of virus transfer should be considered for future HIV therapeutic development.